Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta blockers after myocardial infarction: have trials changed practice?

N S Baber, D G Julian, J A Lewis

    British Medical Journal (Clinical Research Ed.)
    |November 24, 1984
    PubMed
    Summary

    British cardiologists commonly prescribe long-term beta blockers after myocardial infarction, even without other indications. Prescribing policies vary, but evidence from clinical trials seems integrated into hospital practices.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    The Management of Dysrhythmias in Cardiac Infarction.

    Journal of the Royal College of Physicians of London·2019
    Same author

    Translation of clinical trials into clinical practice.

    Journal of internal medicine·2004
    Same author

    Variability of the SIRT3 gene, human silent information regulator Sir2 homologue, and survivorship in the elderly.

    Experimental gerontology·2003
    Same author

    The allele (A)(-110) in the promoter region of the HSP70-1 gene is unfavorable to longevity in women.

    Biogerontology·2003
    Same author

    The study of APOA1, APOC3 and APOA4 variability in healthy ageing people reveals another paradox in the oldest old subjects.

    Annals of human genetics·2003
    Same author

    The influences on human longevity by HUMTHO1.STR polymorphism (Tyrosine Hydroxylase gene). A relative risk approach.

    Mechanisms of ageing and development·2002

    Area of Science:

    • Cardiology
    • Clinical Practice
    • Evidence-Based Medicine

    Background:

    • Beta blockers are frequently prescribed following myocardial infarction (MI).
    • Guidelines recommend beta blockers for secondary prevention post-MI.
    • Understanding current prescribing practices is crucial for adherence to evidence-based medicine.

    Purpose of the Study:

    • To survey British consultant cardiologists regarding their long-term beta blocker prescribing habits after myocardial infarction.
    • To assess the extent of prophylactic beta blocker use in the absence of other indications.
    • To evaluate the assimilation of clinical trial evidence into routine practice.

    Main Methods:

    • A survey was conducted among British consultant cardiologists.
    • The survey focused on current practices for prescribing long-term beta blockers post-myocardial infarction.

    Related Experiment Videos

  • Data on prophylactic use and specific prescribing policies were collected.

    • Main Results:

    • 72% of surveyed cardiologists reported using beta blockers prophylactically after myocardial infarction, even without other indications.
    • Significant variation exists in the specific policies and details of beta blocker prescription among respondents.
    • Favorable clinical trial evidence appears to be incorporated into hospital practice.

    Conclusions:

    • Long-term beta blocker prescription after myocardial infarction is a common practice among British cardiologists.
    • While prophylactic use is widespread, prescribing protocols show considerable variability.
    • Evidence from clinical trials has seemingly been integrated into standard hospital care for post-MI patients.